FDA — authorised 7 February 2017
- Marketing authorisation holder: KAI PHARMS INC
- Status: approved
🇺🇸 Parsabiv in United States
FDA authorised Parsabiv on 7 February 2017
Marketing authorisations
FDA — authorised 7 February 2017
- Application: NDA208325
- Marketing authorisation holder: KAI PHARMS INC
- Local brand name: PARSABIV
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
Parsabiv in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Parsabiv approved in United States?
Yes. FDA authorised it on 7 February 2017; FDA authorised it on 7 February 2017.
Who is the marketing authorisation holder for Parsabiv in United States?
KAI PHARMS INC holds the US marketing authorisation.